CEI warned policy makers a couple decades ago that an Environmental Protection Agency (EPA) phase out of over-the-counter sales of CFC containing asthma inhalers would threaten public health without providing environmental benefits. These products had been safely used for nearly 50 years, but EPA decided that the public should have limited access because of overblown concerns about their potential to harm the ozone layer. Because of that ban, asthmatics can only access asthma inhalers by prescription. Congress is considering reversing — albeit only temporarily — this crazy policy thanks to a campaign launched by Amphastar, the makers of Primatene Mist CFC inhalers. Read the full article on OpenMarket.org.